Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)
Conditions
Interventions
Sofosbuvir
Glecaprevir/Pibrentasvir
+1 more
Locations
26
United States
Digestive Health Specialists of the Southeast /ID# 155719
Dothan, Alabama, United States
Ruane Clinical Research Group /ID# 155714
Los Angeles, California, United States
Digestive Disease Associates - Baltimore /ID# 155713
Baltimore, Maryland, United States
Henry Ford Health System /ID# 155720
Detroit, Michigan, United States
University of Buffalo /ID# 155721
Buffalo, New York, United States
Carolinas Center For Liver Dis /ID# 155731
Statesville, North Carolina, United States
Start Date
November 21, 2016
Primary Completion Date
May 7, 2021
Completion Date
July 30, 2021
Last Updated
May 4, 2022
NCT06718530
NCT05361603
NCT05975216
NCT05071261
NCT05906459
NCT04980157
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions